Movement Alert｜Praxis Precision Medicines Falls 5.15% in Regular Trading, FDA Extends Relutrigine Review Period by Three Months

Market Focus07-02

On July 2, Praxis Precision Medicines fell 5.15% in regular trading, trading at approximately $318.22/share, with turnover of $84.89 million.

The decline was triggered by the FDA announcing an extension of the review period for the company's core drug Relutrigine by three months. The New Drug Application (NDA) covers the treatment of SCN2A and SCN8A-related developmental and epileptic encephalopathies. The FDA had previously set a PDUFA target action date of September 27, meaning the potential approval timeline is now pushed further out, pressuring market expectations for the company's commercialization progress.

Praxis had originally planned to submit the Relutrigine NDA by mid-February and received the September PDUFA date in late March. The company's pipeline also includes Vormatrigine, which showed favorable tolerability with discontinuation rates below 10%, and Elsunersen, which reported positive Phase A results in the Embrave trial for SCN2A early-onset developmental epileptic encephalopathy. However, the delay in Relutrigine — the most advanced commercial candidate — weighs on near-term sentiment.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1165233809?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-02 01:20","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1165233809","market":"us","top_or_hot":-1,"title":"Movement Alert｜Praxis Precision Medicines Falls 5.15% in Regular Trading, FDA Extends Relutrigine Review Period by Three Months","media":"Market Focus","content":"<p><p>On July 2, Praxis Precision Medicines fell 5.15% in regular trading, trading at approximately $318.22/share, with turnover of $84.89 million.</p><p>The decline was triggered by the FDA announcing an extension of the review period for the company's core drug Relutrigine by three months. The New Drug Application (NDA) covers the treatment of SCN2A and SCN8A-related developmental and epileptic encephalopathies. The FDA had previously set a PDUFA target action date of September 27, meaning the potential approval timeline is now pushed further out, pressuring market expectations for the company's commercialization progress.</p><p>Praxis had originally planned to submit the Relutrigine NDA by mid-February and received the September PDUFA date in late March. The company's pipeline also includes Vormatrigine, which showed favorable tolerability with discontinuation rates below 10%, and Elsunersen, which reported positive Phase A results in the Embrave trial for SCN2A early-onset developmental epileptic encephalopathy. However, the delay in Relutrigine — the most advanced commercial candidate — weighs on near-term sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Praxis Precision Medicines Falls 5.15% in Regular Trading, FDA Extends Relutrigine Review Period by Three Months</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Praxis Precision Medicines Falls 5.15% in Regular Trading, FDA Extends Relutrigine Review Period by Three Months\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-07-02 01:20</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On July 2, Praxis Precision Medicines fell 5.15% in regular trading, trading at approximately $318.22/share, with turnover of $84.89 million.</p><p>The decline was triggered by the FDA announcing an extension of the review period for the company's core drug Relutrigine by three months. The New Drug Application (NDA) covers the treatment of SCN2A and SCN8A-related developmental and epileptic encephalopathies. The FDA had previously set a PDUFA target action date of September 27, meaning the potential approval timeline is now pushed further out, pressuring market expectations for the company's commercialization progress.</p><p>Praxis had originally planned to submit the Relutrigine NDA by mid-February and received the September PDUFA date in late March. The company's pipeline also includes Vormatrigine, which showed favorable tolerability with discontinuation rates below 10%, and Elsunersen, which reported positive Phase A results in the Embrave trial for SCN2A early-onset developmental epileptic encephalopathy. However, the delay in Relutrigine — the most advanced commercial candidate — weighs on near-term sentiment.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"PRAX","symbol_name":"Praxis Precision Medicines, Inc.","start_time":0,"source_url":"","article_id":"1165233809","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1165233809","pubTimestamp":1782926406,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On July 2, Praxis Precision Medicines fell 5.15% in regular trading, trading at approximately $318.22/share, with turnover of $84.89 million.The decline was triggered by the FDA announcing an...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"PRAX":"Praxis Precision Medicines, Inc."},"translate_title":"动静快讯|Praxis Precision Medicines常规交易下跌5.15%FDA将Relutrigine审查期延长三个月","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"PRAX":1},"content_text":"On July 2, Praxis Precision Medicines fell 5.15% in regular trading, trading at approximately $318.22/share, with turnover of $84.89 million.The decline was triggered by the FDA announcing an extension of the review period for the company's core drug Relutrigine by three months. The New Drug Application (NDA) covers the treatment of SCN2A and SCN8A-related developmental and epileptic encephalopathies. The FDA had previously set a PDUFA target action date of September 27, meaning the potential approval timeline is now pushed further out, pressuring market expectations for the company's commercialization progress.Praxis had originally planned to submit the Relutrigine NDA by mid-February and received the September PDUFA date in late March. The company's pipeline also includes Vormatrigine, which showed favorable tolerability with discontinuation rates below 10%, and Elsunersen, which reported positive Phase A results in the Embrave trial for SCN2A early-onset developmental epileptic encephalopathy. However, the delay in Relutrigine — the most advanced commercial candidate — weighs on near-term sentiment.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"-1","news_tag":"policyRegulatory","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.45.2","shortVersion":"4.45.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1165233809","isCrawlerRequest":true}